Displaying 1 publication

Abstract:
Sort:
  1. Alemtuzumab as Remission Induction Therapy in Behçet Disease: A 20-year Experience
    Mohammad AJ, Smith RM, Chow YW, Chaudhry AN, Jayne DR
    J Rheumatol, 2015 Oct;42(10):1906-13.
    PMID: 26276966 DOI: 10.3899/jrheum.141344
    To study the efficacy and safety of anti-CD52 antibody (alemtuzumab) in the treatment of refractory and relapsing Behçet disease (BD).
Related Terms
    Try searching for something
Filters
Contact Us

Please provide feedback to Administrator (afdal@afpm.org.my)

External Links